Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer

[1]  M. Ouellette,et al.  Mutant p53R175H promotes cancer initiation in the pancreas by stabilizing HSP70. , 2019, Cancer letters.

[2]  He Li,et al.  Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis. , 2019, Pathology, research and practice.

[3]  Min Young Yoo,et al.  Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. , 2019, Cancer research.

[4]  Danfeng Shi,et al.  Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non‐small‐cell lung cancer (NSCLC) , 2018, Chemical biology & drug design.

[5]  J. Weinstein,et al.  Predicting high-risk endometrioid carcinomas using proteins , 2018, Oncotarget.

[6]  S. Myung,et al.  Clinical implications of the Hippo-YAP pathway in multiple cancer contexts , 2018, BMB reports.

[7]  Jing Wang,et al.  Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer , 2018, Oncotarget.

[8]  Jeffrey S. Morris,et al.  Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival , 2017, Annals of Surgical Oncology.

[9]  Srijit Das,et al.  The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications. , 2017, Current drug targets.

[10]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[11]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[12]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[13]  C. Iacobuzio-Donahue,et al.  p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells , 2016, Oncogene.

[14]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[15]  S. Dupont,et al.  Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. , 2016, Trends in cell biology.

[16]  Xiaolong Yang,et al.  Roles of the Hippo pathway in lung development and tumorigenesis , 2016, International journal of cancer.

[17]  G. Gores,et al.  A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma* , 2016, The Journal of Biological Chemistry.

[18]  Lin Xu,et al.  PKM2 and cancer: The function of PKM2 beyond glycolysis , 2016, Oncology letters.

[19]  Yongzhi Yang,et al.  Hippo‐YAP signaling pathway: A new paradigm for cancer therapy , 2015, International journal of cancer.

[20]  M. V. Vander Heiden,et al.  The Role of Pyruvate Kinase M2 in Cancer Metabolism , 2015, Brain pathology.

[21]  J. Sage,et al.  Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway , 2015, Molecular Cancer Research.

[22]  J. Downward,et al.  Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer , 2015, Current protocols in pharmacology.

[23]  C. Creighton,et al.  Reverse phase protein arrays in signaling pathways: a data integration perspective , 2015, Drug design, development and therapy.

[24]  Jeremy J. W. Chen,et al.  R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Kimmelman,et al.  Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.

[26]  L. Teng,et al.  YAP/TAZ for cancer therapy: opportunities and challenges (review). , 2015, International journal of oncology.

[27]  M. Sander,et al.  Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors , 2015, Development.

[28]  Kun-Liang Guan,et al.  The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.

[29]  Nansheng Chen,et al.  Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.

[30]  William J. Israelsen,et al.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. , 2014, Molecular cell.

[31]  L. Dwyer-Nield,et al.  Depletion of Tumor-Associated Macrophages Slows the Growth of Chemically Induced Mouse Lung Adenocarcinomas , 2014, Front. Immunol..

[32]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[33]  Yingyong Hou,et al.  YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression , 2014, Nature Communications.

[34]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[36]  R. Herbst,et al.  A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[37]  Stephen L. Abrams,et al.  Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. , 2014, Current pharmaceutical design.

[38]  A. Berns,et al.  Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[39]  Weiwei Yang,et al.  Nuclear PKM2 regulates the Warburg effect , 2013, Cell cycle.

[40]  H. Lu,et al.  Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo , 2013, Cancer Gene Therapy.

[41]  P. He,et al.  Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Yingyong Hou,et al.  [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma]. , 2012, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[43]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[44]  H. Grabsch,et al.  KRAS and BRAF mutations in Nigerian colorectal cancers. , 2012, West African journal of medicine.

[45]  Rui Ju,et al.  Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. , 2012, European journal of cancer.

[46]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[47]  Haiquan Chen,et al.  Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. , 2011, Lung cancer.

[48]  F. Camargo,et al.  Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance , 2011, Proceedings of the National Academy of Sciences.

[49]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[50]  G. Halder,et al.  Hippo signaling: growth control and beyond , 2011, Development.

[51]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[52]  E. Wang,et al.  Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer , 2010, Cancer science.

[53]  Ju-Seog Lee,et al.  Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver , 2010, Proceedings of the National Academy of Sciences.

[54]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[55]  Jeannie T. Lee,et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.

[56]  L. Hesson,et al.  RASSF2 associates with and stabilizes the proapoptotic kinase MST2 , 2009, Oncogene.

[57]  Li Zhang,et al.  Serial dilution curve: a new method for analysis of reverse phase protein array data , 2009, Bioinform..

[58]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[59]  P. Yelick,et al.  The pro‐apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1 , 2007, The EMBO journal.

[60]  Steffen Hauptmann,et al.  Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma , 2007, Molecular carcinogenesis.

[61]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[62]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[63]  Jianbin Huang,et al.  The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP , 2005, Cell.

[64]  A. Berns,et al.  Mouse models for human lung cancer. , 2005, Genes & development.

[65]  F. DeMayo,et al.  Genetically engineered mouse models for lung cancer , 2005 .

[66]  L. Johansson.  Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. , 2004, Annals of diagnostic pathology.

[67]  E. Eigenbrodt,et al.  Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. , 2003, Cancer letters.

[68]  T. Jacks,et al.  Modeling human lung cancer in mice: similarities and shortcomings , 1999, Oncogene.

[69]  M. Miller.  Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1A1 on lung cancer initiation. , 1994, Chemical research in toxicology.

[70]  A. Malkinson.  The genetic basis of susceptibility to lung tumors in mice. , 1989, Toxicology.

[71]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[72]  K. Linnet,et al.  Differential diagnostic value in hepatobiliary disease of serum conjugated bile acid concentrations and some routine liver tests assessed by discriminant analysis. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[73]  T. K. Eisinger-Mathason,et al.  Targeting the Hippo pathway: Clinical implications and therapeutics. , 2016, Pharmacological research.

[74]  A. Jemal,et al.  Global Cancer Statistics , 2011 .